News | Mammography | September 01, 2017

Nationwide survey reveals nearly half of all inspections had one or more deficiencies related to mammography quality assessment processes

FDA Releases Six-Month Inspection Data From EQUIP Mammography Quality Initiative

September 1, 2017 — The Division of Mammography Quality Standards (DMQS) of the U.S. Food and Drug Administration (FDA) released new data from an analysis of inspections performed under the Enhancing Quality Using the Inspection Program (EQUIP) initiative. All data was collected from Jan. 1, 2017, through June 30, 2017.

Announced by the FDA in October 2016, the EQUIP program was created to ensure mammography facilities are adhering to the highest standards when assessing the quality of their mammograms. The program added three questions to the regular inspection process and eliminated two.

During this first year of inspections that include the EQUIP questions, facilities will not receive citations related to the new EQUIP questions. However, inspectors are responsible for recording facility responses to the EQUIP questions and any deficiencies are noted on the post-inspection report. These are then discussed during the inspection close-out session so that facilities are aware of what would have been cited if citations were in effect. This provides facilities with the opportunity to address these deficiencies prior to inspection citations being issued, beginning with inspections performed on or after Jan. 1, 2018.

As of June 30, 2017, there have been 4,166 annual MQSA inspections performed under the EQUIP initiative. Overall, 44 percent of those inspections had one or more EQUIP deficiencies. The chart below shows a breakdown of how many deficient inspections were recorded for each EQUIP sub-question. The highest number of deficient inspections was related to sub-questions 2(a) and 2(b), which cover the periodic image quality review.

EQUIP Question No. of Deficient Inspections Percent of Total Inspections
Question 1(a) - There is no system in place that includes a mechanism for providing ongoing IP feedback on image quality 542 13%
Question 1(b) - There is no system in place that includes a mechanism for documenting any needed corrective action and the effectiveness of any corrective action taken 1,045 25%
Question 2(a) - There is no mechanism in place for regular reviews of image quality attributes of a sample of mammograms performed by each active RT and a sample of mammograms accepted for interpretation by each active IP 1,421 34%
Question 2(b) - There is no documentation of review since the last inspection 1,263 30%
Question 3(a) - There is no system in place for LIP oversight, including review of the frequency of performance of all required tests 803 19%
Question 3(b) - There is no system in place for LIP review to determine whether appropriate corrective actions were performed when needed 937 22%

The DMQS said it had anticipated that Question 2 might be the most difficult for facilities to meet, mainly due to the fact that while many facilities engage in daily feedback, not all of them take the opportunity to do an assessment of image quality for the facility as a whole, including all technologists and interpreting physicians in that assessment. This type of assessment allows the facility an overall look at the quality of the breast images it produces, as well as a look at the less-often-assessed quality of images that its interpreting physicians are accepting for interpretation. Image quality is a responsibility that should be shared by both technologists and interpreting physicians. Supplementing the daily feedback process with this type of assessment can potentially lead to systemic remedies that improve a facility’s image quality, according to the DMQS. Although the division encourages facilities to do this assessment more frequently, it must be done and documented at least once a year.

The agency note that the EQUIP questions are designed to check that processes are in place for this image quality review, not specific review details. Facilities are free to design processes that best fit their individual situations and practices. This flexibility allows for many different ways to successfully meet Question 2, as well as the other EQUIP questions, and thereby satisfy the EQUIP inspection questions.

DMQS encourages providers to please take time to engage with their inspector during this educational year to learn how EQUIP can help the facility maintain image quality. Beginning with inspections performed on or after Jan. 1, 2018, Level 2 citations will be issued to facilities who have not successfully implemented the processes covered by the EQUIP inspection questions.

For more information: www.fda.gov


Related Content

News | Breast Imaging

July 29, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the ...

Time July 29, 2024
arrow
News | Breast Imaging

July 29, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time July 29, 2024
arrow
News | Radiology Business

July 25, 2024 — The radiology gender gap is decreasing, but there remains work to be done, according to an editorial ...

Time July 25, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Flat Panel Displays

July 17, 2024 — LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic ...

Time July 17, 2024
arrow
Feature | Imaging Technology News - ITN

Be sure to check out the latest digital edition of Imaging Technology News (ITN), featuring the Mobile C-arm Systems ...

Time July 11, 2024
arrow
News | Artificial Intelligence

July 9, 2024 — Lunit, a provider of Artificial Intelligence (AI)-powered solutions for cancer diagnostics and ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
Feature | Radiology Business

The ITN team wishes you a safe and happy 4th of July!

Time July 04, 2024
arrow
Subscribe Now